MA52795B1 - Dérivés de carbamoylpyridone polycycliques pour le traitement du vih - Google Patents
Dérivés de carbamoylpyridone polycycliques pour le traitement du vihInfo
- Publication number
- MA52795B1 MA52795B1 MA52795A MA52795A MA52795B1 MA 52795 B1 MA52795 B1 MA 52795B1 MA 52795 A MA52795 A MA 52795A MA 52795 A MA52795 A MA 52795A MA 52795 B1 MA52795 B1 MA 52795B1
- Authority
- MA
- Morocco
- Prior art keywords
- sup
- hiv
- treatment
- img
- ring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La présente invention concerne un composé représenté par la formule (I) : <img file="imga0001.tif" frnum="0001" he="29" id="ia01" img-content="chem" img-format="tif" inline="no" orientation="portrait" pgnum="0001" wi="72"/> dans laquelle le cycle A est un hétérocycle substitué ou non substitué ; le cycle C est un cycle benzénique ou similaire ; R<sup>1</sup> est un halogène ou similaire ; R<sup>2a</sup> et R<sup>2b</sup> sont chacun indépendamment un hydrogène ou similaire ; R<sup>3</sup> est un alkyle substitué ou non substitué ou similaire ; R<sup>4</sup> est un hydrogène ou similaire ; et n est un entier de 1 à 3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018104156 | 2018-05-31 | ||
| PCT/JP2019/021446 WO2019230858A1 (fr) | 2018-05-31 | 2019-05-30 | Dérivé de carbamoylpyridone polycyclique |
| EP19810498.6A EP3805220B1 (fr) | 2018-05-31 | 2019-05-30 | Dérivés de carbamoylpyridone polycycliques pour le traitement du vih |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52795A MA52795A (fr) | 2021-04-14 |
| MA52795B1 true MA52795B1 (fr) | 2024-09-30 |
Family
ID=68698918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52795A MA52795B1 (fr) | 2018-05-31 | 2019-05-30 | Dérivés de carbamoylpyridone polycycliques pour le traitement du vih |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US11649236B2 (fr) |
| EP (2) | EP3805220B1 (fr) |
| JP (2) | JP7328962B2 (fr) |
| KR (2) | KR20250002769A (fr) |
| CN (2) | CN117327072A (fr) |
| AR (1) | AR115455A1 (fr) |
| AU (2) | AU2019277548B2 (fr) |
| BR (1) | BR112020024077A2 (fr) |
| CA (1) | CA3102063A1 (fr) |
| CL (1) | CL2020003002A1 (fr) |
| CO (1) | CO2020014294A2 (fr) |
| CR (2) | CR20200644A (fr) |
| DK (1) | DK3805220T3 (fr) |
| DO (1) | DOP2020000221A (fr) |
| EA (1) | EA202092921A1 (fr) |
| ES (1) | ES2984245T3 (fr) |
| FI (1) | FI3805220T3 (fr) |
| HR (1) | HRP20241221T1 (fr) |
| HU (1) | HUE068170T2 (fr) |
| IL (2) | IL279051B2 (fr) |
| LT (1) | LT3805220T (fr) |
| MA (1) | MA52795B1 (fr) |
| MD (1) | MD3805220T2 (fr) |
| MX (2) | MX2020012176A (fr) |
| MY (1) | MY198568A (fr) |
| PE (2) | PE20251594A1 (fr) |
| PH (1) | PH12020552000A1 (fr) |
| PL (1) | PL3805220T3 (fr) |
| PT (1) | PT3805220T (fr) |
| RS (1) | RS65891B1 (fr) |
| SG (1) | SG11202011382PA (fr) |
| SI (1) | SI3805220T1 (fr) |
| SM (1) | SMT202400330T1 (fr) |
| UA (1) | UA129229C2 (fr) |
| WO (1) | WO2019230858A1 (fr) |
| ZA (1) | ZA202007567B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119462659A (zh) | 2019-03-22 | 2025-02-18 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其药学用途 |
| US20230058677A1 (en) * | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Polycyclic pyridopyrazine derivative |
| US20230059640A1 (en) * | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
| AU2021225809B2 (en) | 2020-02-24 | 2023-08-24 | Gilead Sciences, Inc. | Tetracyclic compounds for treating HIV infection |
| WO2021233302A1 (fr) * | 2020-05-21 | 2021-11-25 | 南京明德新药研发有限公司 | Dérivés cycliques fusionnés et leur utilisation en pharmacie |
| US20240018145A1 (en) * | 2020-07-27 | 2024-01-18 | Merck Sharp & Dohme Llc | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
| JP7691494B2 (ja) | 2020-09-30 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | 架橋三環式カルバモイルピリドン化合物及びその使用 |
| HRP20231654T2 (hr) | 2021-01-19 | 2025-01-03 | Gilead Sciences, Inc. | Supstituirani spojevi piridotriazina i njihove uporabe |
| WO2023006087A1 (fr) * | 2021-07-30 | 2023-02-02 | 南京明德新药研发有限公司 | Composé de pyridone macrocyclique et son application |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024061257A1 (fr) * | 2022-09-20 | 2024-03-28 | 吉斯凯(苏州)制药有限公司 | Composé cétone n-hétérocyclique polycyclique et son utilisation |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006506352A (ja) | 2002-09-11 | 2006-02-23 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物 |
| HRP20050593A2 (en) | 2002-12-27 | 2006-03-31 | Instituto di Ricerche di Biologia Molecolare P. An | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| JP5317257B2 (ja) | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体 |
| ES2567197T3 (es) | 2005-04-28 | 2016-04-20 | Viiv Healthcare Company | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH |
| JP5131689B2 (ja) | 2005-10-27 | 2013-01-30 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 |
| SG183484A1 (en) | 2010-02-26 | 2012-09-27 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| JP5766690B2 (ja) | 2010-04-12 | 2015-08-19 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有するピリドン誘導体 |
| KR20140090197A (ko) | 2011-10-12 | 2014-07-16 | 시오노기세야쿠 가부시키가이샤 | 인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체 |
| WO2014099586A1 (fr) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih |
| AP2015008510A0 (en) | 2012-12-21 | 2015-06-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| PE20151063A1 (es) | 2012-12-27 | 2015-08-03 | Japan Tobacco Inc | DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH |
| WO2014183532A1 (fr) | 2013-05-17 | 2014-11-20 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih |
| US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| NO2865735T3 (fr) | 2013-07-12 | 2018-07-21 | ||
| PL3252058T3 (pl) | 2013-07-12 | 2021-07-19 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| WO2015039348A1 (fr) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih |
| EA030695B1 (ru) | 2013-09-27 | 2018-09-28 | Мерк Шарп И Доум Корп. | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич |
| WO2015089847A1 (fr) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih |
| WO2015199167A1 (fr) | 2014-06-25 | 2015-12-30 | 日本たばこ産業株式会社 | PROCÉDÉ POUR PRÉPARER UN DÉRIVÉ SUBSTITUÉ DE SPIROPYRIDO[1,2-a]PYRAZINE ET INTERMÉDIAIRE |
| JPWO2016027879A1 (ja) | 2014-08-22 | 2017-06-01 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| WO2016090545A1 (fr) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Composés hétérocycliques spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih |
| US10150780B2 (en) | 2014-12-09 | 2018-12-11 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as HIV integrase inhibitors |
| TWI738321B (zh) * | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| US10081647B2 (en) | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| ES2718410T3 (es) | 2015-04-02 | 2019-07-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica |
| WO2016187788A1 (fr) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih |
| WO2017087256A1 (fr) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Dérivés de pyridotriazine spirocyclique utiles en tant qu'inhibiteurs de l'intégrase du vih |
| US10548910B2 (en) | 2015-11-17 | 2020-02-04 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors |
| EP3389380B1 (fr) | 2015-12-15 | 2021-07-21 | Merck Sharp & Dohme Corp. | Dérivés de quinolizine spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih |
| WO2017113288A1 (fr) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tricycliques condensés utiles en tant qu'inhibiteurs de l'intégrase du vih |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| CN110062627A (zh) | 2016-12-02 | 2019-07-26 | 默沙东公司 | 可用作hiv整合酶抑制剂的三环杂环化合物 |
| WO2019160783A1 (fr) | 2018-02-15 | 2019-08-22 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih |
| EP3784241A4 (fr) | 2018-04-27 | 2022-01-19 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih |
| CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| AU2019277547B2 (en) | 2018-05-31 | 2024-10-10 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
| US11884683B2 (en) | 2018-06-05 | 2024-01-30 | Merck Sharp & Dohme Llc | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| CN108957755B (zh) | 2018-07-27 | 2021-04-30 | 京东方科技集团股份有限公司 | 一种显示组件及其控制方法、平视显示器及汽车 |
| CN119462659A (zh) | 2019-03-22 | 2025-02-18 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其药学用途 |
-
2019
- 2019-05-30 KR KR1020247040377A patent/KR20250002769A/ko active Pending
- 2019-05-30 AR ARP190101467A patent/AR115455A1/es unknown
- 2019-05-30 HU HUE19810498A patent/HUE068170T2/hu unknown
- 2019-05-30 SG SG11202011382PA patent/SG11202011382PA/en unknown
- 2019-05-30 US US17/058,251 patent/US11649236B2/en active Active
- 2019-05-30 PL PL19810498.6T patent/PL3805220T3/pl unknown
- 2019-05-30 EA EA202092921A patent/EA202092921A1/ru unknown
- 2019-05-30 ES ES19810498T patent/ES2984245T3/es active Active
- 2019-05-30 CN CN202311258763.1A patent/CN117327072A/zh active Pending
- 2019-05-30 KR KR1020207037580A patent/KR102741390B1/ko active Active
- 2019-05-30 UA UAA202008303A patent/UA129229C2/uk unknown
- 2019-05-30 CA CA3102063A patent/CA3102063A1/fr active Pending
- 2019-05-30 CN CN201980050399.5A patent/CN112513042B/zh active Active
- 2019-05-30 PE PE2025000789A patent/PE20251594A1/es unknown
- 2019-05-30 PT PT198104986T patent/PT3805220T/pt unknown
- 2019-05-30 JP JP2020522577A patent/JP7328962B2/ja active Active
- 2019-05-30 AU AU2019277548A patent/AU2019277548B2/en active Active
- 2019-05-30 EP EP19810498.6A patent/EP3805220B1/fr active Active
- 2019-05-30 IL IL279051A patent/IL279051B2/en unknown
- 2019-05-30 BR BR112020024077-0A patent/BR112020024077A2/pt unknown
- 2019-05-30 DK DK19810498.6T patent/DK3805220T3/da active
- 2019-05-30 EP EP23192706.2A patent/EP4257137A3/fr active Pending
- 2019-05-30 HR HRP20241221TT patent/HRP20241221T1/hr unknown
- 2019-05-30 MY MYPI2020006045A patent/MY198568A/en unknown
- 2019-05-30 PE PE2020001863A patent/PE20210477A1/es unknown
- 2019-05-30 SI SI201930798T patent/SI3805220T1/sl unknown
- 2019-05-30 LT LTEPPCT/JP2019/021446T patent/LT3805220T/lt unknown
- 2019-05-30 RS RS20240971A patent/RS65891B1/sr unknown
- 2019-05-30 FI FIEP19810498.6T patent/FI3805220T3/fi active
- 2019-05-30 SM SM20240330T patent/SMT202400330T1/it unknown
- 2019-05-30 MX MX2020012176A patent/MX2020012176A/es unknown
- 2019-05-30 WO PCT/JP2019/021446 patent/WO2019230858A1/fr not_active Ceased
- 2019-05-30 MA MA52795A patent/MA52795B1/fr unknown
- 2019-05-30 CR CR20200644A patent/CR20200644A/es unknown
- 2019-05-30 MD MDE20210334T patent/MD3805220T2/ro unknown
- 2019-05-30 IL IL313474A patent/IL313474A/en unknown
- 2019-05-30 CR CR20230571A patent/CR20230571A/es unknown
-
2020
- 2020-11-13 MX MX2023010377A patent/MX2023010377A/es unknown
- 2020-11-18 CO CONC2020/0014294A patent/CO2020014294A2/es unknown
- 2020-11-18 CL CL2020003002A patent/CL2020003002A1/es unknown
- 2020-11-20 PH PH12020552000A patent/PH12020552000A1/en unknown
- 2020-11-27 DO DO2020000221A patent/DOP2020000221A/es unknown
- 2020-12-04 ZA ZA2020/07567A patent/ZA202007567B/en unknown
-
2023
- 2023-03-22 US US18/124,827 patent/US12139489B2/en active Active
- 2023-08-03 JP JP2023127333A patent/JP7679427B2/ja active Active
-
2024
- 2024-02-08 AU AU2024200783A patent/AU2024200783A1/en active Pending
- 2024-06-26 US US18/755,191 patent/US20240352015A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52795B1 (fr) | Dérivés de carbamoylpyridone polycycliques pour le traitement du vih | |
| MA42795A (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| EA202092923A1 (ru) | Полициклическое производное пиридона | |
| MA65131B1 (fr) | Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t | |
| FR3087439B1 (fr) | Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone) | |
| EP4495093A3 (fr) | Composé polycyclique et dispositif électroluminescent organique le comprenant | |
| MA44021A (fr) | Composés antitumoraux | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| MA45020A (fr) | Dérivés sulfonamides aromatiques | |
| MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA41494A (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées | |
| MA53370B1 (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
| FR3061183B1 (fr) | Compose du cobalt utile comme catalyseur d'hydrosilylation, de silylation deshydrogenante et de reticulation de compositions silicones | |
| FR3066761B1 (fr) | Nouveaux composes inhibiteurs des canaux ioniques | |
| FR3107897B1 (fr) | Dérivés de nicotinamide mononucléotides | |
| FR3037953B1 (fr) | Procede de synthese de molecules portant une fonction oxyde de nitrile | |
| MA28117A1 (fr) | Procédé pour la préparation de composés hétérocycliques à substitution N-amino | |
| MA41885B1 (fr) | Mélange d'additifs | |
| FR3071850B1 (fr) | Composition d’additifs pour carburant | |
| BE1026157A1 (fr) | Sel, generateur d'acide, composition de resist et procede pour produire un motif de resist | |
| MA64128B1 (fr) | Inhibiteurs de tead | |
| MX2023008250A (es) | Compuestos de derivados sustituidos en 4,6 de ip4. | |
| FR3108502B1 (fr) | Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes | |
| RU2007143501A (ru) | ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, КОТОРЫЕ МОЖНО ИСПОЛЬЗОВАТЬ В КАЧЕСТВЕ ИНГИБИТОРОВ ПЕПТИДДЕФОРМИЛАЗЫ (ПДФ) | |
| MA53138B1 (fr) | Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) |